Ferritin and the Full Iron Panel: Optimal Levels, Iron Stores, and Complete Interpretation

Medical disclaimer: This article is for educational and research purposes only. It does not constitute medical advice. Reference ranges and clinical thresholds vary between laboratories and depend on individual clinical context. Always consult a qualified Australian healthcare practitioner before making decisions about iron supplementation, genetic testing, or treatment based on ferritin results.

---

Ferritin is simultaneously the most useful and the most misinterpreted marker in iron metabolism. On one hand, it is the best available single measure of total body iron stores — a window into the reserves held in hepatocytes, macrophages, and bone marrow that sustains iron supply to every cell in the body. On the other hand, ferritin is an acute-phase reactant: the liver synthesises more of it in response to inflammatory signals, entirely independent of how much iron is actually stored.

That duality creates a diagnostic trap. A ferritin of 120 µg/L returned as "within normal limits" may represent adequate iron stores in an otherwise healthy person — or it may represent near-depleted stores in someone with chronic low-grade inflammation, whose ferritin has been artificially inflated by cytokine signals rather than by iron. Without concurrent context, including a CRP or hs-CRP result, the number alone cannot be decoded.

This article examines what ferritin actually is at a biochemical level, what the Australian reference ranges mean and where they fall short, the evidence behind functional optimal targets, how to interpret both low and high ferritin correctly, and the emerging evidence linking elevated ferritin to cardiometabolic risk through mechanisms entirely distinct from iron overload.

---

What Ferritin Is: The Iron-Apoferritin Shell Complex

Ferritin is a hollow protein shell — apoferritin — composed of 24 subunits arranged into a cage-like structure roughly 12 nanometres in diameter. Inside that cage, the protein can sequester up to 4,500 iron atoms as ferric oxyhydroxide, holding iron in a soluble, non-toxic, and bioavailable form.

The biology behind this storage mechanism matters for interpretation:

• Intracellular function: Ferritin's primary role is intracellular. Inside liver cells, macrophages, and bone marrow cells, ferritin sequesters excess iron and releases it on demand via regulated degradation (ferritinophagy). This protects cells from the oxidative damage that free iron would otherwise cause.
• Serum ferritin: A small fraction of intracellular ferritin is secreted into the bloodstream. This serum ferritin fraction is largely iron-poor compared with the intracellular form, but its concentration in circulation closely tracks the size of the body's intracellular iron stores — which is why it is used as a surrogate measure of total body iron.
• The storage signal: When iron stores are high, ferritin synthesis is upregulated via iron-responsive elements (IREs) on the ferritin mRNA. When stores fall, ferritin synthesis is suppressed. This makes serum ferritin a reliable proxy for iron status under normal physiological conditions — but not under inflammatory conditions, where a second set of regulatory signals overrides the iron-sensing mechanism.

In short, ferritin is normally an iron sensor. Under inflammation, it becomes an inflammation sensor. The same number can mean very different things depending on the inflammatory environment in which it was produced.

---

Australian Reference Ranges: What the Lab Cutoffs Actually Represent

According to ptex.au — the Australasian pathology reference cited by the Australian Government's My Health Record — standard reference ranges for serum ferritin in Australian pathology are:

These ranges represent the central 95th percentile of the tested population. That is a statistical construct, not a clinical one. A ferritin of 30 µg/L in a man, or 15 µg/L in a woman, sits right at the lower boundary of "normal" in the statistical sense — but in physiological terms, it represents near-depletion of iron stores. The body's iron reserves at these levels are marginal at best.

This distinction matters in everyday clinical practice. A woman with a ferritin of 18 µg/L will receive a result marked "within normal limits" on most Australian pathology reports. Yet at that level she is operating with minimal iron reserves — enough to avoid frank anaemia under resting conditions, but insufficient to support the many non-haematopoietic functions that depend on iron: thyroid peroxidase activity, dopaminergic neurotransmission, mitochondrial electron transport, and hair follicle cycling.

The reference range tells you where the statistical boundary of the tested population falls. It does not tell you where optimal function begins.

---

Functional Optimal Targets: What the Evidence Supports

Functional medicine practitioners and a growing number of haematologists and GPs use a narrower and higher target range for ferritin that reflects the research on symptom thresholds rather than population statistics.

For women of reproductive age, the 50–100 µg/L range emerges consistently in the literature on iron-related symptoms. Hair loss (telogen effluvium) studies have found that ferritin below 40–50 µg/L is associated with increased hair shedding, and that hair regrowth improves when ferritin rises above 70 µg/L. Thyroid function research identifies ferritin below 50 µg/L as a factor impairing T4-to-T3 conversion via reduced thyroid peroxidase activity. Fatigue and cognitive impairment research similarly shows symptom thresholds in the 30–50 µg/L range — well above the laboratory lower bound of 15 µg/L.

For men, the 70–150 µg/L range is supported by data on energy metabolism, cognitive function, and exercise recovery. The higher lower bound reflects both the higher absolute iron stores men typically carry and the lower baseline inflammatory background that makes ferritin a more reliable iron signal in men than in cycling or pregnant women.

The contrast between the functional optimal floor (50 µg/L for women) and the laboratory lower bound (15 µg/L for women) represents the most commonly missed clinical gap in Australian primary care: tissue iron depletion that causes real, measurable symptoms but produces a result reported as normal.

---

The Dual Nature Problem: Ferritin as an Acute-Phase Reactant

Understanding ferritin's inflammatory behaviour is the single most important concept in interpreting any ferritin result.

When the immune system is activated — by infection, autoimmune disease, metabolic inflammation, or tissue injury — the liver mounts an acute-phase response. Hepatocytes ramp up synthesis of several proteins, including CRP, fibrinogen, and ferritin. The upstream signals driving this response are primarily interleukin-6 (IL-6) and, to a lesser extent, interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α).

The acute-phase upregulation of ferritin is independent of iron status. The liver does not produce more ferritin because there is more iron to store — it produces more ferritin because the inflammatory milieu instructs it to. The biological rationale is partly protective: sequestering iron into ferritin reduces the free iron available to iron-dependent pathogens, a phenomenon known as "nutritional immunity."

The clinical consequence is that inflammation inflates ferritin artificially. A person with chronic low-grade inflammation — metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), chronic low-level infection, or even obesity — may carry a ferritin in the 100–200 µg/L range that looks reassuring but conceals genuinely depleted iron stores. Their actual tissue iron status may be poor; the ferritin number is elevated by IL-6 production rather than by iron.

The practical rule: Ferritin cannot be interpreted accurately without concurrent CRP. Specifically:

• If ferritin is elevated and CRP is also elevated (>5 mg/L on standard CRP, or >1 mg/L on hs-CRP), the ferritin elevation may reflect inflammation rather than iron overload. Retest once the inflammatory trigger resolves.
• If ferritin appears normal but CRP is elevated, the true iron stores may be lower than ferritin suggests. Consider transferrin saturation and soluble transferrin receptor to clarify.
• If ferritin is elevated and CRP is normal, the elevated ferritin warrants investigation for genuine iron overload — particularly haemochromatosis.

For a full treatment of CRP interpretation and inflammatory risk assessment, see CRP and hs-CRP optimal levels.

---

Low Ferritin: Iron Deficiency Before Anaemia

The most important clinical concept in ferritin interpretation is that iron depletion causes symptoms long before haemoglobin falls. This state — iron deficiency without anaemia, sometimes called non-anaemic iron deficiency or tissue iron depletion — is the most prevalent and most under-treated iron disorder in Australian practice.

Why Symptoms Precede Anaemia

The bone marrow preferentially directs available iron toward haemoglobin synthesis. As stores decline, erythropoiesis is maintained at the expense of other iron-dependent processes: myoglobin in muscle tissue, cytochrome c and iron-sulphur clusters in mitochondria, dopamine synthesis enzymes in the brain, thyroid peroxidase in the thyroid. By the time haemoglobin falls, the body has already been operating with compromised cellular iron metabolism for months.

This produces a recognisable symptom cluster at ferritin levels well above the anaemia threshold:

• Persistent fatigue and reduced exercise tolerance
• Cognitive impairment — brain fog, poor concentration, word-finding difficulty
• Hair loss (telogen effluvium — diffuse shedding typically beginning 6–12 weeks after stores fall)
• Restless legs syndrome (iron is required for dopamine synthesis in the striatum)
• Cold intolerance — impaired peripheral thermogenesis
• Reduced immune function

All of these can present when ferritin is 20–45 µg/L — technically "within range" by most laboratory standards, and with a completely normal haemoglobin.

Treatment Options

Dietary iron: Haem iron from red meat provides 20–30% absorption; non-haem iron from legumes, seeds, and leafy greens provides 2–10%. Consuming vitamin C alongside non-haem sources doubles absorption by reducing ferric (Fe³⁺) to the absorbable ferrous (Fe²⁺) form.

Oral supplementation — ferrous vs ferric vs bisglycinate: Ferrous sulfate (the most commonly prescribed form in Australia) provides approximately 65 mg of elemental iron per 200 mg tablet and is effective but frequently causes GI side effects — constipation, nausea, and dark stools. Ferrous gluconate and ferrous fumarate are alternative ferrous salts with marginally better tolerability profiles. Ferric forms (ferric carboxymaltose is the IV preparation; ferric polymaltose is used orally) are less well absorbed in oral formulations compared with ferrous forms. Ferrous bisglycinate (chelated iron) provides lower elemental iron doses but superior mucosal uptake efficiency — the glycinate chelation protects iron from dietary inhibitors and improves absorption across the enterocyte membrane — with substantially better tolerability than iron salts. Alternate-day dosing is supported by research from the Lancet Haematology (Stoffel et al., 2017) showing that daily dosing triggers hepcidin upregulation that suppresses next-day absorption; every-other-day dosing improves overall iron absorbed per dose.

Intravenous iron: Available via GP or specialist referral for severe deficiency (ferritin below 15 µg/L with symptoms), failed oral supplementation, malabsorption syndromes, or rapid repletion requirements. IV iron bypasses GI absorption entirely and can raise ferritin by 100–200 µg/L in a single infusion.

The full supplementation protocol — cofactors, alternate-day dosing, and duration — is detailed in the iron supplementation section below.

---

High Ferritin: The Two-Step Interpretation Protocol

An elevated ferritin result — particularly above 200–300 µg/L — should never be accepted at face value. The first question is always whether the elevation reflects genuine iron excess or inflammatory upregulation.

Step 1: Check CRP

Concurrent CRP is essential. If CRP is elevated alongside ferritin, inflammation is likely driving at least part of the ferritin elevation. Identify and address the inflammatory source — infection, autoimmune disease, NAFLD, metabolic syndrome, alcohol use — before interpreting ferritin as an indicator of iron overload.

Common causes of inflammation-driven high ferritin:

• Metabolic syndrome and obesity: Visceral adipose tissue secretes IL-6 continuously, chronically elevating both CRP and ferritin. Ferritin in the 150–400 µg/L range is common in people with central obesity and insulin resistance, even without any iron overload.
• Non-alcoholic fatty liver disease (NAFLD/MASLD): Hepatic inflammation from lipid accumulation drives ferritin elevation via both acute-phase signalling and direct hepatocellular release of stored ferritin. GGT and ALT/AST provide complementary information — see the ALT and AST liver enzyme guide.
• Alcohol excess: Alcohol elevates ferritin through liver inflammation, impaired ferritin clearance, and direct hepatotoxicity. Ferritin of 200–600 µg/L in someone with significant alcohol intake is common and reflects liver status rather than iron overload.
• Chronic infection and autoimmune disease: Any persistently activated immune state will upregulate ferritin via IL-6.

Step 2: Assess Transferrin Saturation

If CRP is normal and ferritin remains elevated, the next step is transferrin saturation (TSAT) on a fasting morning sample. A TSAT above 45% on a fasted sample is the primary screening marker for hereditary haemochromatosis and warrants HFE gene testing.

---

Haemochromatosis: The Iron Overload Diagnosis Most Commonly Missed

Hereditary haemochromatosis (HH) is one of the most prevalent single-gene disorders in Australia. The HFE gene on chromosome 6 encodes a protein that regulates hepcidin — the hepatic hormone that governs intestinal iron absorption. When HFE is mutated, hepcidin production is inappropriately low, and the intestine continues absorbing iron regardless of body stores. Over years to decades, iron accumulates in parenchymal organs.

Prevalence in the Australian population: Approximately 1 in 200 Australians of Northern European (particularly Irish, Scottish, and Scandinavian) descent carries two copies of the C282Y mutation — the primary pathogenic variant — making homozygous HFE haemochromatosis highly prevalent in the Australian context. The compound heterozygous state (one copy of C282Y and one copy of H63D) is also clinically significant and similarly prevalent.

The screening protocol:

The critical point: fasting transferrin saturation rises before ferritin becomes dramatically elevated. Ferritin can appear within or near the reference range in early-stage haemochromatosis while TSAT is already above 50%. This is why TSAT, not ferritin, is the most sensitive early screen.

Treatment: Regular therapeutic venesection (phlebotomy) — removing 450–500 mL of blood every 1–2 weeks during the depletion phase, then maintenance every 2–4 months — is definitive, simple, safe, and inexpensive. When initiated before significant organ iron deposition, life expectancy is normal. Untreated, progressive iron accumulation leads to liver cirrhosis, hepatocellular carcinoma, cardiomyopathy, diabetes, hypogonadism, and arthropathy.

---

Ferritin and Cardiometabolic Risk: The Fenton Reaction Connection

Beyond haemochromatosis, there is an independent and under-recognised connection between elevated ferritin and cardiometabolic disease in people without clinical iron overload. The mechanism is oxidative stress mediated by free iron.

The Fenton reaction describes the chemistry at the core of iron-catalysed oxidative damage: ferrous iron (Fe²⁺) reacts with hydrogen peroxide to produce hydroxyl radical (•OH) — one of the most reactive and destructive oxidising species in biology. Hydroxyl radical attacks lipid membranes, oxidises LDL particles (producing atherogenic oxLDL), damages mitochondrial DNA, and induces hepatocellular injury.

When iron stores are elevated above the physiological optimum — even in the sub-haemochromatosis range — the risk of this Fenton chemistry increases, particularly in the context of metabolic disease where hydrogen peroxide production from dysfunctional mitochondria is already elevated.

The epidemiological picture is consistent with this mechanism:

• Elevated ferritin (in the range of 200–400 µg/L, independent of CRP) is associated in prospective studies with increased risk of type 2 diabetes, metabolic syndrome, and NAFLD — after adjustment for inflammatory markers.
• Observational data from large cohorts link ferritin in the upper-normal range to insulin resistance via mechanisms consistent with hepatic iron-mediated oxidative stress impairing insulin signalling.
• The association between elevated ferritin and uric acid is noteworthy — uric acid functions partly as an antioxidant scavenging free iron, and its elevation in metabolic syndrome may reflect a compensatory response to iron-driven oxidative stress. The connection between uric acid and metabolic health is explored in uric acid as a metabolic marker.

This cardiometabolic connection reinforces the value of keeping ferritin within the functional optimal range rather than simply below the laboratory upper bound. For most adults, ferritin progressively drifting toward 250–400 µg/L without a clear inflammatory trigger warrants investigation and consideration of dietary iron reduction, increased blood donation, and monitoring of transferrin saturation.

---

The Full Iron Panel: Reading Ferritin Alongside Every Other Marker

Ferritin is the most important single marker of iron stores, but it cannot be interpreted in isolation — it is an acute-phase reactant, and its meaning changes depending on the rest of the panel. A complete iron studies panel triangulates supply, transport, storage, and tissue demand. A standard "iron studies" request in Australian pathology returns five markers; a full panel extends to seven.

The first five are returned with any "iron studies" request. Transferrin saturation is calculated (serum iron ÷ TIBC × 100) and reported automatically; UIBC is calculated (TIBC − serum iron). Soluble transferrin receptor must be requested specifically and attracts an additional cost. Always collect iron studies fasting — an overnight fast of 8–12 hours is required, because dietary iron absorbed in the hours before the draw can substantially elevate serum iron and transferrin saturation, producing a falsely reassuring result. A concurrent full blood count (FBC) supplies essential context — see CBC blood test optimal ranges.

Serum Iron: Informative Only in Context

Serum iron measures the iron circulating in plasma, bound to transferrin. It is the most volatile marker on the panel — fluctuating with time of day, recent diet, illness, menstrual cycle phase, and stress.

Functional optimal is roughly 14–25 µmol/L on a fasted morning sample. A low serum iron could reflect genuine deficiency, anaemia of chronic disease, or simple diurnal variation; a high value could reflect haemochromatosis, recent supplementation, or haemolysis. The number means little without TIBC and ferritin alongside it.

Transferrin and TIBC: Reading Iron Demand

Transferrin is the glycoprotein that carries iron through the bloodstream. The body upregulates transferrin production when iron is scarce — a compensatory response to capture more of the available circulating iron. TIBC is effectively a calculated expression of transferrin concentration.

Elevated transferrin/TIBC signals iron deficiency — more transport protein is made to capture scarce iron. Suppressed transferrin/TIBC is seen in inflammation, liver disease, malnutrition, and iron overload. This interplay is decisive in distinguishing true iron deficiency (ferritin low, transferrin high) from anaemia of chronic disease (ferritin normal/elevated, transferrin suppressed — the inflammatory state inverts the expected pattern).

UIBC: The Spare-Capacity Signal

UIBC (unsaturated iron binding capacity) is TIBC minus serum iron — the spare carrying capacity not yet occupied by iron (reference range approximately 25–55 µmol/L). Elevated UIBC indicates iron deficiency (most binding sites unoccupied); low UIBC indicates iron loading or suppressed transferrin. UIBC is largely redundant with TIBC and TSAT but provides a third independent angle when transferrin and serum iron are discordant.

Transferrin Saturation: The Most Actionable Marker

Transferrin saturation (TSAT = serum iron ÷ TIBC × 100) is the percentage of transferrin's capacity occupied by iron — a direct measure of iron delivery to tissues. It is the key marker for two opposite scenarios: deficiency (very low) and overload (very high).

TSAT below 16% with ferritin below 50 µg/L is the most reliable combined indicator of clinically significant iron deficiency, regardless of haemoglobin. TSAT above 45% on a fasting morning sample is the key screen for hereditary haemochromatosis — it rises years before ferritin becomes markedly elevated.

Soluble Transferrin Receptor: The Marker Most Panels Miss

Soluble transferrin receptor (sTfR) is shed from cell surfaces — particularly erythroid precursors — when cells are starved of iron. It reflects aggregate tissue iron demand independent of inflammation, which is its crucial advantage: sTfR rises in true iron deficiency and stays normal in anaemia of chronic disease, cutting through the ambiguity that makes ferritin unreliable in inflammatory states.

Request sTfR specifically when iron deficiency is suspected alongside elevated CRP or known inflammatory disease, in anaemia complicating rheumatoid arthritis or IBD, when monitoring iron deficiency in pregnancy, or in equivocal microcytic/normocytic anaemia. It is not universally Medicare-rebatable and typically attracts a $30–$60 out-of-pocket cost.

---

Optimal vs Reference Ranges: The Full-Panel View

The most clinically significant gap across the whole panel is ferritin in premenopausal women, but every marker has a functional optimal that is narrower than its statistical reference range.

---

Iron Deficiency Without Anaemia: The Most Commonly Missed Pattern

Iron deficiency without anaemia (IDWA) — also called non-anaemic or pre-anaemic iron deficiency — is the state in which iron stores are depleted enough to cause symptoms but haemoglobin has not yet fallen below the anaemia threshold. It is the most common and most under-treated pattern in iron metabolism.

The body prioritises haemoglobin synthesis: as stores fall, the marrow directs available iron to red-cell production at the expense of myoglobin, mitochondrial enzymes, neurotransmitter synthesis, and thyroid peroxidase. Haemoglobin stays normal while almost everything else iron-dependent is compromised.

It gets missed because the standard GP workflow often requests FBC alone when fatigue or hair loss is the complaint; a normal haemoglobin returns "normal" without iron studies, or iron studies show ferritin 18–40 µg/L reported as "within normal limits." The fix is simple: request a full iron panel including ferritin and TSAT whenever iron deficiency is clinically suspected, regardless of the FBC result.

---

Causes of Low Ferritin

• Menorrhagia (heavy menstrual bleeding): the single most common cause in premenopausal women — blood loss above ~80 mL per cycle exceeds dietary iron absorption.
• Gastrointestinal blood loss: the most important cause in men and postmenopausal women (peptic ulcer, colorectal cancer/polyps, coeliac disease, IBD, angiodysplasia, regular aspirin/NSAID use). Any man or postmenopausal woman with iron deficiency should have GI blood loss excluded before it is attributed to diet.
• Low dietary intake: haem iron (red meat, poultry, fish) is 20–30% absorbed; non-haem iron (legumes, leafy greens, tofu, fortified cereals) only 2–10%. Vegetarians/vegans require ~1.8× the omnivore intake.
• Malabsorption: coeliac disease, H. pylori, proton pump inhibitors, gastric bypass, and IBD all impair duodenal iron absorption.
• High athletic demand: foot-strike haemolysis, exercise-induced GI ischaemia, sweat losses, and training-driven erythropoiesis leave many endurance athletes at ferritin 20–50 µg/L.

---

Reading the Panel as a System: Diagnostic Patterns

The combined IDA + ACD pattern is the most diagnostically challenging, and is precisely where sTfR is decisive — elevated in true iron deficiency regardless of inflammatory context, and normal in pure ACD.

---

Iron Supplementation: Cofactors, Dosing, and Duration

Correcting low ferritin is not simply a matter of taking iron — absorption is modulated by dosing schedule, co-ingested nutrients, and gastric conditions.

Alternate-Day Dosing

Research published in the Lancet Haematology (Stoffel et al., 2017) demonstrated that alternate-day iron dosing produces greater absorption than daily dosing. A single dose raises serum hepcidin — the hormone that blocks intestinal iron uptake — and that elevation suppresses absorption from any dose taken later the same day and the next morning. Spacing doses every second day lets hepcidin fall, so each dose is absorbed more efficiently (fractional absorption ~21.8% on alternate days versus ~16.3% on consecutive days). Practical recommendation: take iron on alternate days, in the morning, on an empty stomach (or with a little food if GI tolerance is a problem).

Enhancers and Inhibitors of Absorption

Forms and Duration

Ferrous sulfate (~65 mg elemental iron per 200 mg tablet) is the most commonly prescribed form in Australia — effective but frequently causes constipation, nausea, and dark stools. Ferrous bisglycinate (chelated iron) is better tolerated with comparable or superior absorption despite lower elemental doses. Low-dose liquid preparations (Spatone, Floradix) suit maintenance or mild deficiency. Intravenous iron (ferric carboxymaltose) is available via GP or specialist referral for severe deficiency, malabsorption, or failed oral therapy, and can raise ferritin by 100–200 µg/L per infusion. Continue oral supplementation for 3 months after ferritin reaches target (not merely after haemoglobin normalises), and recheck iron studies at 8–12 weeks; if ferritin is not rising, reassess dosing technique, absorption (coeliac, H. pylori, PPI use), and ongoing blood loss.

For the bioavailability of different dietary and supplemental iron forms, see iron supplementation bioavailability.

---

Iron, Mitochondria, and Endocrine Function

Iron's role in energy production extends well beyond haemoglobin. Iron is an essential component of the mitochondrial electron transport chain — iron-sulphur clusters in Complexes I, II, and III, and cytochrome c — so without adequate iron, cellular ATP generation is impaired independently of any effect on red cells. This is why fatigue in iron deficiency often precedes anaemia, and why restoring haemoglobin without fully restoring ferritin frequently leaves patients symptomatic. The same iron dependence applies to mitochondrial energy production in the brain.

Iron deficiency also has downstream endocrine effects. Iron is required for thyroid peroxidase (impairing T4 synthesis and T4→T3 conversion, producing hypothyroid symptoms even when TSH is normal) and for cytochrome P450 enzymes in cortisol synthesis. When iron deficiency is identified, a concurrent thyroid panel and a cortisol and DHEA adrenal panel give a fuller picture of the hormonal consequences.

---

Testing Access in Australia

Iron studies (serum iron, ferritin, transferrin, TIBC, transferrin saturation) are Medicare-rebatable with clinical indication via a GP. Soluble transferrin receptor is not universally rebatable and may require specialist ordering or a gap payment; HFE gene testing is rebatable when transferrin saturation is elevated or family history is established. Full iron panels are available privately without a GP referral for approximately $60–$130 depending on provider and whether sTfR or HFE testing is added. For current private options, pricing, and turnaround, see the Australian blood testing directory.

---

Ferritin in Context: The Companion Markers

For the liver enzyme picture, see ALT and AST liver enzyme interpretation.

Those following research into peptides and metabolic health — including the intersection of iron metabolism, mitochondrial function, and oxidative stress — can find a summary of the current evidence base at RetaLABS research.

---

Frequently Asked Questions

What ferritin level is considered optimal in Australia? For premenopausal women, functional optimal is 50–150 µg/L; for men and postmenopausal women, 80–200 µg/L. The lab lower reference limit (as low as 12 µg/L for women) represents statistical normality, not functional sufficiency.

Can ferritin be normal but I am still iron deficient? Yes, in two scenarios. First, inflammation artificially elevates ferritin and can mask deficiency (anaemia of chronic disease) — this is where soluble transferrin receptor is decisive. Second, ferritin in the 20–50 µg/L range is technically within the lab reference range but represents suboptimal stores associated with symptoms. Always interpret ferritin alongside transferrin saturation.

My ferritin is 350 µg/L — should I be worried? It depends on context. In a healthy man with no symptoms, 350 µg/L is borderline elevated and warrants a fasting transferrin saturation to screen for haemochromatosis. With recent infection, active inflammation, fatty liver disease, or significant alcohol intake, it may be an acute-phase reaction — repeat testing after the illness resolves and check transferrin saturation.

How quickly does ferritin rise with supplementation? With appropriate supplementation and no ongoing blood loss or malabsorption, ferritin typically rises by 10–20 µg/L per month. Reaching optimal levels from severely depleted stores can take 3–6 months. Recheck at 8–12 weeks.

What is haemochromatosis and how do I screen for it? Hereditary haemochromatosis is a genetic condition causing progressive iron overload. Screening is via fasting transferrin saturation — if above 45%, proceed to HFE gene testing. It is treatable (venesection/phlebotomy) when caught early, before liver, heart, or joint damage occurs. First-degree relatives of confirmed cases should also be screened.

---

Key Takeaways

• Ferritin is an iron-storage protein (apoferritin shell complex) whose serum concentration reflects total body iron stores under normal conditions — but is upregulated by IL-6 and other inflammatory signals independently of iron status.
• Australian reference ranges (men 30–300 µg/L, women 15–200 µg/L, per ptex.au — the Australasian pathology reference linked from the Australian Government My Health Record) represent statistical population cutoffs, not functional sufficiency thresholds.
• Functional optimal targets are 50–100 µg/L for women of reproductive age and 70–150 µg/L for men — derived from symptom threshold research rather than population statistics.
• Low ferritin causes fatigue, hair loss, brain fog, restless legs, and cold intolerance at levels above the anaemia threshold — the pre-anaemic iron deficiency pattern is the most commonly missed finding in Australian primary care.
• High ferritin must be interpreted with concurrent CRP. Elevated ferritin with elevated CRP suggests inflammation is the driver. Elevated ferritin with normal CRP warrants transferrin saturation testing to screen for haemochromatosis.
• Haemochromatosis (HFE C282Y homozygosity) affects approximately 1 in 200 Australians of Northern European descent. Fasting transferrin saturation above 45% is the primary screening signal — it rises before ferritin becomes dramatically elevated.
• Elevated ferritin in the absence of inflammation is associated with insulin resistance, NAFLD, and metabolic syndrome through iron-catalysed oxidative stress via the Fenton reaction.

---

This article is for educational purposes only and does not constitute medical advice. Reference ranges vary between Australian pathology laboratories. Consult a qualified medical practitioner for interpretation of your individual results, before commencing iron supplementation, and before investigation for haemochromatosis.